tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

APLS Stock Latest News

Needham healthcare analysts hold analyst/industry conference call
The FlyNeedham healthcare analysts hold analyst/industry conference call
3h ago
JNJ
NVS
Apellis price target raised to $31 from $30 at Scotiabank
PremiumThe Fly
Apellis price target raised to $31 from $30 at Scotiabank
7h ago
APLS
Promising Outlook for Apellis Pharmaceuticals: Buy Rating Backed by Key Milestones and Attractive Valuation
PremiumRatings
Promising Outlook for Apellis Pharmaceuticals: Buy Rating Backed by Key Milestones and Attractive Valuation
1d ago
APLS
Apellis announces FDA acceptance, priority review of sNDA for EMPAVELI
PremiumThe Fly
Apellis announces FDA acceptance, priority review of sNDA for EMPAVELI
1d ago
APLS
Cautious Hold on Apellis Pharmaceuticals Amid Competitive Landscape and Promising Empaveli Prospects
PremiumRatings
Cautious Hold on Apellis Pharmaceuticals Amid Competitive Landscape and Promising Empaveli Prospects
12d ago
APLS
Morgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli
PremiumThe FlyMorgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli
12d ago
NVS
APLS
Apellis Pharmaceuticals: Favorable Market Positioning and Strong Clinical Results Justify Buy Rating
Premium
Ratings
Apellis Pharmaceuticals: Favorable Market Positioning and Strong Clinical Results Justify Buy Rating
12d ago
APLS
Buy Rating for Apellis Pharmaceuticals Driven by Empaveli’s Market Potential and Efficacy in C3G Treatment
Premium
Ratings
Buy Rating for Apellis Pharmaceuticals Driven by Empaveli’s Market Potential and Efficacy in C3G Treatment
12d ago
APLS
JPMorgan healthcare analysts hold an analyst/industry conference call
PremiumThe Fly
JPMorgan healthcare analysts hold an analyst/industry conference call
15d ago
APLS
Apellis price target raised to $54 from $50 at JPMorgan
PremiumThe Fly
Apellis price target raised to $54 from $50 at JPMorgan
29d ago
APLS
Apellis price target lowered to $29 from $30 at Wedbush
PremiumThe Fly
Apellis price target lowered to $29 from $30 at Wedbush
1M ago
APLS
Positive Long-term Outlook and Strategic Positioning Drive Buy Rating for Apellis Pharmaceuticals
PremiumRatings
Positive Long-term Outlook and Strategic Positioning Drive Buy Rating for Apellis Pharmaceuticals
1M ago
APLS
Apellis price target lowered to $44 from $47 at BofA
PremiumThe FlyApellis price target lowered to $44 from $47 at BofA
1M ago
APLS
Apellis price target lowered to $30 from $31 at Morgan Stanley
Premium
The Fly
Apellis price target lowered to $30 from $31 at Morgan Stanley
1M ago
APLS
Buy Rating for Apellis Pharmaceuticals Driven by Strategic Growth Initiatives and Strong Product Performance
Premium
Ratings
Buy Rating for Apellis Pharmaceuticals Driven by Strategic Growth Initiatives and Strong Product Performance
1M ago
APLS
Hold Rating for Apellis Pharmaceuticals Amidst Market Challenges and Moderate Growth Expectations
PremiumRatings
Hold Rating for Apellis Pharmaceuticals Amidst Market Challenges and Moderate Growth Expectations
1M ago
APLS
Apellis Pharmaceuticals Faces Financial Challenges Amid Ambitious Drug Commercialization Efforts
PremiumCompany Announcements
Apellis Pharmaceuticals Faces Financial Challenges Amid Ambitious Drug Commercialization Efforts
1M ago
APLS
Apellis Pharmaceuticals Reports Strong 2024 Growth
PremiumCompany Announcements
Apellis Pharmaceuticals Reports Strong 2024 Growth
1M ago
APLS
Apellis Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
PremiumCompany Announcements
Apellis Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
1M ago
APLS
Strong Q4 Performance and Strategic Positioning Justify Buy Rating for Apellis Pharmaceuticals
PremiumRatingsStrong Q4 Performance and Strategic Positioning Justify Buy Rating for Apellis Pharmaceuticals
1M ago
APLS
Apellis Pharmaceuticals: Strong Market Presence and Strategic Growth Potential Justify Buy Rating
Premium
Ratings
Apellis Pharmaceuticals: Strong Market Presence and Strategic Growth Potential Justify Buy Rating
1M ago
APLS
Apellis Pharmaceuticals: Strong Buy Rating Maintained Amid Market Share Adjustments
Premium
Ratings
Apellis Pharmaceuticals: Strong Buy Rating Maintained Amid Market Share Adjustments
1M ago
APLS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >